Project Details
| Status | Active |
|---|---|
| Effective start/end date | 06/4/26 → 10/31/27 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $6,604.00
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
- Pili, Roberto (PI)
Project: Research